08:45 - 08:55	23rd Annual ENETS Conference | Welcome and opening

08:55 - 09:00	16th ENETS Postgraduate Course | Welcome and introduction

08:55 - 09:00	Basic science | Welcome and opening

09:00 - 09:15	Decoding NENs for the clinician
	Christos Toumpanakis, GBR

09:15 - 09:30	Decoding NENs for the pathologist: Pitfalls and the limits of small biopsies
	Massimo Milione, ITA

09:30 - 09:45	Decoding NENs for the radiologist: When morphologic imaging fails or misleads
	Clarisse Dromain, SUI

09:45 - 10:00	Decoding NENs for the nuclear medicine specialist: Understanding imaging mismatches
	Lawrence Dierickx, FRA

10:00 - 10:30	Panel discussion

09:00 - 09:25	Normal human enteroendocrine cell differentiation and NET – Is it relevant?
	Ramesh Shivdasani, USA

09:25 - 09:30	Discussion

09:30 - 09:45	Immune landscape in NENs: Any therapeutic potential?
	Stefano La Rosa, ITA

09:45 - 10:00	The role of CAF in microenvironment shaping in small bowel NETs
	Benjamin Gibert, FRA

10:00 - 10:15	Assessing tumour 3D vasculature – What can we learn?
	Axel Mosig, GER

10:15 - 10:20	Discussion

10:20 - 10:30	Mini oral presentation

10:20 - 10:27	Unrevealing spatial differences in a cohort of highly proliferative lung carcinoids with the GeoMx® Digital Spatial Profiler
	Giovanna Sabella, SUI

10:27 - 10:30	Discussion

11:00 - 11:15	Liver-directed, local therapies (SIRT, TACE, RFA)
	Timm Denecke, GER

11:15 - 11:30	Radiofrequency ablation for pancreas (incl. MEN1)
	Francesco Panzuto, ITA

11:30 - 11:45	Bone metastases management
	Maria Wedin, SWE

11:45 - 12:00	Case presentation: MEN1 case with pancreatic, liver and bone lesion involvement
	Maribel Del Olmo Garcia, ESP

12:00 - 12:30	MDT panel discussion

11:00 - 11:15	Impact of VHL in NET tumourogenesis (germline and sporadic)
	Rachel van Leeuwaarde, NED

11:15 - 11:30	Specificities of germline VHL related PanNET
	Louis de Mestier, FRA

11:30 - 11:45	Targeting VHL pathway in sporadic and germline NETs
	Marina Tsoli, GRE

11:45 - 12:00	Discussion

12:00 - 12:10	A clinically relevant morpho-molecular classification of lung neuroendocrine tumours
	Alexandra Sexton-Oates, FRA

12:10 - 12:15	Discussion

12:15 - 12:25	Tracing tumor evolution in pulmonary neuroendocrine cancer using patient-derived tumor organoids
	Heleen Jungen, ESP

12:25 - 12:30	Discussion

13:00 - 14:00	Satellite Symposium I – Industry sponsored

14:00 - 14:15	Lung NET
	Hussein Almeamar, IRL

14:15 - 14:20	Q & A

14:20 - 14:35	Thymic NET
	Staffan Welin, SWE

14:35 - 14:40	Q & A

14:40 - 14:55	Pancreas NET
	Angela Lamarca, ESP

14:55 - 15:00	Q & A

15:00 - 15:15	Extra-pulmonary NEC
	Francesca Spada, ITA

15:15 - 15:20	Q & A

15:20 - 15:30	Panel discussion

14:00 - 14:15	Chromatin remodeling
	Marc Peeters, BEL

14:15 - 14:30	Chromatin landscape in NET
	Paloma Cejas, USA

14:30 - 14:45	MENIN-KMT2A in acute leukaemia
	Michael Kühn, GER

14:45 - 15:00	Discussion

15:00 - 15:30	Mini oral presentations

15:00 - 15:07	The METTL1-tRNA m7G-SMOC1 axis promotes pancreatic neuroendocrine neoplasms proliferation by driving cell cycle progression
	Xu Han, CHN

15:07 - 15:10	Discussion

15:10 - 15:17	Standardised platform for drug screening and risk assessment in patient-derived gastroenteropancreatic neuroendocrine neoplasms
	Katharina Wang, GER

15:17 - 15:20	Discussion

15:20 - 15:27	Integrative gene regulatory network analysis reveals mutation-specific transcriptional programs in pancreatic neuroendocrine tumors
	Pawlak Geoffrey, FRA

15:27 - 15:30	Discussion

16:00 - 16:05	Case presentation: Metastatic functional SiNET grade 2 well-differentiated NET with advanced peritoneal mesenteric disease
	Krystallenia Alexandraki, GRE

16:05 - 16:20	Treatment option 1: Surgery
	Els Nieveen van Dijkum, NED

16:20 - 16:35	Treatment option 2: Nuclear Medicine
	Hans Hofland, NED

16:35 - 16:50	Treatment option 3: Medical Oncology
	Adina Croitoru, ROU

16:50 - 16:55	Vote from the audience

16:55 - 17:25	MDT panel discussion

17:25 - 17:30	Vote from the audience

16:00 - 16:15	NEC subtypes across organs
	Jérôme Cros, FRA

16:15 - 16:30	Biology & targeting of DLL3
	Moritz Jesinghaus, GER

16:30 - 16:45	Cell origin in NEC (MiNEN)
	Marco Volante, ITA

16:45 - 17:00	Discussion

17:00 - 17:15	Oral abstract presentation

17:00 - 17:10	Histological classification of high-grade digestive neuroendocrine neoplasms using an advanced deep learning model
	Matthieu Tihy, FRA

17:10 - 17:15	Discussion

17:15 - 17:35	Mini oral presentations

17:15 - 17:22	Evolution of neuroendocrine and adenocarcinoma components in colorectal mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN)
	Siren Morken, NOR

17:22 - 17:25	Discussion

17:25 - 17:32	PRKDC inhibition as a novel radiosensitization strategy in advanced prostate cancer through NHEJ-targeted synthetic lethality
	Haowen Lu, CHN

17:32 - 17:35	Discussion

17:30 - 17:40	16th ENETS Postgraduate Course | Closing comments

17:35 - 17:40	Basic science | Closing comments

17:40 - 18:00	ENETS Projects

18:00 - 18:30	WELCOME RECEPTION

07:45 - 08:45	Satellite Symposium II – Industry sponsored

09:00 - 09:15	SSTR pathway
	Maria Chiara Zatelli, ITA

09:15 - 09:20	Discussion

09:20 - 09:35	Angiogenesis
	Jennifer Chan, USA

09:35 - 09:40	Discussion

09:40 - 09:55	Immunotherapy
	Thomas Walter, FRA

09:55 - 10:00	Discussion

10:00 - 10:30	Oral abstract presentations

10:00 - 10:10	DAREON®-7: Phase I open-label dose-escalation/expansion study of first-line obrixtamig (BI 764532) plus platinum-doublet chemotherapy in patients with DLL3-positive neuroendocrine carcinomas
	Jaume Capdevila, ESP

10:10 - 10:15	Discussion

10:15 - 10:25	Investigator-assessed disease progression in a phase 2 study of paltusotine in patients with neuroendocrine tumors and carcinoid syndrome
	Łukasz Hajac, POL

10:25 - 10:30	Discussion

11:00 - 11:15	Imaging and molecular profile of PPGL
	Karel Pacak, CZE

11:15 - 11:20	Discussion

11:20 - 11:35	Surgical approach to PPGL
	Georgios Zografos, GRE

11:35 - 11:40	Discussion

11:40 - 11:55	Advances in the treatment of PPGL
	Julien Hadoux, FRA

11:55 - 12:00	Discussion

12:00 - 12:15	Genetic counselling of PPGL
	Louise Izatt, GBR

12:15 - 12:25	Discussion

12:25 - 12:30	Wrap-up

11:00 - 11:30	Oral abstract presentations

11:00 - 11:10	Treatment, recurrence and survival in 277 patients with stage I-III digestive neuroendocrine carcinoma – Preliminary results from an ENETS initiated retrospective cohort study
	Halfdan Sorbye, NOR

11:10 - 11:15	Discussion

11:15 - 11:25	Spatial immune landscape identifies microenvironmental predictors of immunotherapy efficacy in grade 3 digestive neuroendocrine neoplasms
	Beatriz Anton Pascual, CAN

11:25 - 11:30	Discussion

11:30 - 12:30	Mini oral presentations

11:30 - 11:37	First-line streptozotocin vs temozolomide-based chemotherapy in advanced neuroendocrine tumors: Real-world comparison from the Spanish GETNE registry
	Alejandro Garcia-Alvarez, ESP

11:37 - 11:40	Discussion

11:40 - 11:47	A phase II study of cabozantinib and temozolomide in advanced neuroendocrine tumors
	Giuseppina Della Vittoria Scarpati, ITA

11:47 - 11:50	Discussion

11:50 - 11:57	177Lu-edotreotide for the treatment of pancreatic neuroendocrine tumours: A subgroup analysis from the COMPETE study
	Thomas Walter, FRA

11:57 - 12:00	Discussion

12:00 - 12:07	Efficacy and safety of retreatment PRRT – A multi-centre Australian study
	David Chan, AUS

12:07 - 12:10	Discussion

12:10 - 12:17	Clinical relevance of comprehensive genomic and transcriptomic profiling in advanced epithelial neuroendocrine neoplasms: Results from the MASTER precision oncology program
	Leonidas Apostolidis, GER

12:17 - 12:20	Discussion

12:20 - 12:27	Pulmonary neuroendocrine tumour artificial intelligence-assisted prediction of postoperative recurrence from tumour biopsy specimens
	Teodora-Elena Trandafir, NED

12:27 - 12:30	Discussion

13:00 - 14:30	Satellite Symposium III – Industry sponsored

14:30 - 14:42	Impact of systemic anticancer therapies on QoL and PROs in NENs
	John Ramage, GBR

14:42 - 14:54	Management of toxicities of emerging therapies in NENs
	Jaume Capdevila, ESP

14:54 - 15:06	Balancing efficacy and safety in management of NET
	Anna Koumarianou, GRE

15:06 - 15:20	Discussion (Guest: Teodora Kolarova – INCA)

15:20 - 15:35	Oral abstract presentation

15:20 - 15:30	First analysis of CABONEN – A multi-center phase II trial investigating Cabozantinib in patients with advanced, low proliferative NEN G3
	Alexander Koenig, GER

15:30 - 15:35	Discussion

14:30 - 14:37	Dissecting the interplay between RNA splicing and m6A methylation in neuroendocrine neoplasms biology
	Daniel Ruiz-Palacios, ESP

14:37 - 14:40	Discussion

14:40 - 14:47	AGR2-high cells drive a FOXM1-mediated pro-malignancy program in non-functional pancreatic neuroendocrine tumors (NF- PanNETs) and informatively predict patient outcomes
	Junya Peng, CHN

14:47 - 14:50	Discussion

14:50 - 14:57	DNA methylation-based classifier identifies prognostically distinct subtypes of pancreatic neuroendocrine tumors
	Simona Avanthay, SUI

14:57 - 15:00	Discussion

15:00 - 15:07	Transcriptomic analysis of small intestinal neuroendocrine tumors reveals reduced REST expression and enteroendocrine cells as cell of origin
	Felix Bolduan, GER

15:07 - 15:10	Discussion

15:10 - 15:17	Unravelling the molecular mechanisms behind mesenteric fibrosis: Analysing epigenetic and transcriptomic profiles for target gene identification
	Maria Ines Castanho Martins, GBR

15:17 - 15:20	Discussion

15:20 - 15:27	Transcriptomic abnormalities of familial small intestine neuroendocrine tumors: A study from the French GTE-RENATEN network
	Thomas Hunaut, FRA

15:27 - 15:30	Discussion

15:30 - 15:37	Characteristics and outcome of VIPoma – A retrospective analysis of the ENETS Database
	Detlef Bartsch, GER

15:37 - 15:40	Discussion

15:40 - 15:50	Laudatio
	Gregory Kaltsas, GRE

15:50 - 16:00	Awardee acceptance
	Ashley Grossman, GBR

16:15 - 16:45	Satellite Symposium IV – Industry sponsored

16:45 - 17:00	NENs in children, adolescents, and young adults: From epidemiology to management
	Rachel Riechelmann, BRA

17:00 - 17:15	Childhood NEN: Clues for genetic predisposition
	Bernadette van Nesselrooij, NED

17:15 - 17:30	Effect of NENs and their therapy on reproductive health and sexual function
	Beata Kos-Kudła, POL

17:30 - 17:45	Neuroendocrine tumours and pregnancy
	Fedro Peccatori, ITA

17:45 - 18:00	Discussion

18:00 - 18:15	Oral abstract presentation

18:00 - 18:10	Early initiation of small intestine neuroendocrine tumors
	Erik Elias, SWE

18:10 - 18:15	Discussion

16:45 - 16:48	Opening
	Rocio Garcia-Carbonero, ESP / Teodora Kolarova, BUL

16:48 - 17:00	The potential of AI in improving NEN research
	Thorvardur Halfdanarson, USA

17:00 - 17:10	Clinical Trials Finder – Using AI to optimise understanding and access
	Danielle Ralic, SUI

17:10 - 17:20	How can AI empower patients
	Teodora Kolarova, BUL

17:20 - 17:32	AI and radiomics: What the future holds
	David Chan, AUS

17:32 - 17:45	AI in support of clinical education and shared decision-making
	Simona Barbi, ITA

17:45 - 17:57	The role of AI in clinical practice
	Raj Srirajaskanthan, GBR

17:57 - 18:12	Discussion

18:12 - 18:15	Wrap-up and close
	Rocio Garcia-Carbonero, ESP / Teodora Kolarova, BUL

18:30 - 18:35	Rescuing refractory G3 neuroendocrine neoplasms (NEN): Real-world clinical outcomes of alpha-PRRT using the SSTR antagonist DOTA-LM3
	Elisabetta Perrone, ITA

18:35 - 18:38	Discussion

18:38 - 18:43	Real-world effectiveness of lanreotide autogel (LAN) in advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs), stratified by Ki-67 proliferation index (Ki-67) and primary tumour location: Post-hoc analyses from KINETICS
	Timon Vandamme, BEL

18:43 - 18:46	Discussion

18:46 - 18:51	An artificial intelligence–assisted, interpretable prognostic tool for mortality risk in lung neuroendocrine tumors
	Francesca Spada, ITA

18:51 - 18:54	Discussion

18:54 - 18:59	Capecitabine/temozolomide or single agent temozolomide in typical and atypical lung neuroendocrine tumours
	Yannick Van Loocke, BEL

18:59 - 19:02	Discussion

19:02 - 19:07	Neuroendocrine neoplasms in young adults: Clinicopathologic profile and survival – Outcomes from the R-GETNE registry
	Diana Rosero, ESP

19:07 - 19:10	Discussion

19:10 - 19:15	Assessment of the selected coagulation parameters in risk prediction of the venous thromboembolic events in neuroendocrine tumours
	Monika Wójcik-Giertuga, POL

19:15 - 19:18	Discussion

19:18 - 19:23	Is resection of small bowel primary NET justified in stage IV disease? Evidence from 2,400 patients in two national population-based registries
	Ker Shiong Tan, GBR

19:23 - 19:26	Discussion

19:26 - 19:30	Wrap-up

18:30 - 18:35	Drug-tolerant pannen cells as precursors of acquired resistance: Opportunities for early intervention against relapse
	Camilla Ullmann, SUI

18:35 - 18:39	Discussion

18:39 - 18:44	How an old dog learns new tricks: GNAS splicing as a potential contributing driver to dedifferentiation in lung neuroendocrine tumors (LungNETs)
	Sergio Pedraza-Arévalo, ESP

18:44 - 18:48	Discussion

18:48 - 18:53	Deciphering the mechanisms of IGF2-mediated liver metastases in pancreatic neuroendocrine tumor through single-cell RNA sequencing
	Nuerailaguli Jumai, CHN

18:53 - 18:57	Discussion

18:57 - 19:02	Understanding the role of extracellular vesicles in small intestinal neuroendocrine tumors
	Deepti Nabariya, GER

19:02 - 19:06	Discussion

19:06 - 19:11	Imaging and molecular annotation of the small intestinal neuroendocrine tumour microenvironment
	Manfredi D'Afflitto, GBR

19:11 - 19:15	Discussion

19:15 - 19:20	Multiomics characterization of multifocal small intestine neuroendocrine tumors
	Alice Schiller, SWE

19:20 - 19:24	Discussion

19:24 - 19:30	Wrap-up

08:00 - 08:10	Introduction: Case presentation
	Els Nieveen van Dijkum, NED

08:10 - 08:25	Why does oligo-progression occur?
	Ilaria Marinoni, SUI

08:25 - 08:40	Systemic therapies for oligo-progression
	Simron Singh, CAN

08:40 - 08:55	Loco-regional therapy for metastatic oligo-progression
	Rafael Duran, SUI

08:55 - 09:10	Surgery for oligo metastatic disease
	Alain Sauvanet, FRA

09:10 - 09:20	Q&A

09:20 - 09:30	Wrap-up
	Stefano Partelli, ITA

07:50 - 07:57	Metabolomic profiles and sex-specific metabolic and survival phenotypes in neuroendocrine neoplasms: Findings from the UK biobank
	Aurimas Kalendauskas, GBR

07:57 - 08:00	Discussion

08:00 - 08:07	Cytoreductive hepatectomy remains effective in carcinoid heart disease
	Vanja Podrascanin, AUT

08:07 - 08:10	Discussion

08:10 - 08:17	Liver transplantation in patients with neuroendocrine tumors – The Oslo experience
	Espen Thiis-Evensen, NOR

08:17 - 08:20	Discussion

08:20 - 08:27	A phase I trial of the oncolytic virus svv-001 with nivolumab and ipilimumab in patients with high-grade neuroendocrine neoplasms
	Aman Chauhan, USA

08:27 - 08:30	Discussion

08:30 - 08:37	Updated results of surufatinib plus transarterial embolization versus surufatinib monotherapy in neuroendocrine tumor with liver metastasis: A prospective, randomized, controlled trial
	Dan Cao, CHN

08:37 - 08:40	Discussion

08:40 - 08:47	Is it time to screen for second primary malignancies in gastroenteropancreatic neuroendocrine tumour? A population-based analysis of 85,614 patients
	Mohamed Mortagy, GBR

08:47 - 08:50	Discussion

08:50 - 08:57	Post-operative patient-reported symptom burden in entero-pancreatic neuroendocrine tumors – A population-level analysis
	Carlotta Sarzo, ITA

08:57 - 09:00	Discussion

09:00 - 09:07	Molecular and immune landscape of early-onset versus average-onset well-differentiated enteropancreatic neuroendocrine tumors
	Udhayvir Grewal, USA

09:07 - 09:10	Discussion

09:10 - 09:17	Comparison of circulating tumour DNA (ctDNA) across NEN subtypes and investigation of ctDNA clinical utility in the care of patients with neuroendocrine neoplasms
	Emma Boehm, AUS

09:17 - 09:20	Discussion

09:20 - 09:27	Complementary roles of patient-derived tumoroids and precision-cut tumor slices in evaluating targeted therapy response in non-functioning pancreatic neuroendocrine tumors
	Anna Battistella, ITA

09:27 - 09:30	Discussion

10:00 - 10:15	Standardised reporting for NET PET: State-of-the-art versus real world experience
	Wolfgang Fendler, GER

10:15 - 10:30	SSTR PET and response assessment
	Christophe Deroose, BEL

10:30 - 10:45	Current state of SSTR-targeted radioligand therapy
	Tessa Brabander, NED

10:45 - 11:00	Novel radiopharmaceuticals for NET: Beyond targeting SSTR
	Julia Fricke, SUI

11:00 - 11:15	Discussion

11:15 - 11:30	Oral abstract presentation

11:15 - 11:25	Dosimetry-guided radioligand therapy in neuroendocrine tumors: Interim safety analysis of the DUONEN trial
	Maciej Kołodziej, POL

11:25 - 11:30	Discussion

11:30 - 11:40	Mini oral presentation

11:30 - 11:37	Phase I trial of M3814 (Peposertib) in combination with lutetium 177 DOTATATE for metastatic well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
	Aman Chauhan, USA

11:37 - 11:40	Discussion

10:00 - 10:05	Welcome
	Wendy Martin, GBR

10:05 - 10:20	Specialist nurse practitioner role in managing patients undergoing radioligand therapy
	Sanne van der Stelt, NED

10:20 - 10:25	Discussion

10:25 - 10:40	How to start a nursing/dietitian research project
	Rachael Delderfield, GBR

10:40 - 10:45	Discussion

10:45 - 11:15	Oral abstract presentations

10:45 - 10:55	Lived experiences and biopsychosocial challenges in the daily lives of patients affected by multiple endocrine neoplasia type 1
	Salomé Vignon, FRA

10:55 - 11:00	Discussion

11:00 - 11:10	Enhancing clinical trial access for NEN patients through a cross-site ‘flying’ study coordinator within NETwerk – ENETS Centre of Excellence
	Caro De Weerdt, BEL

11:10 - 11:15	Discussion

11:15 - 11:30	Results Nurses & Dietitian Questionnaire
	Wanda Geilvoet, NED

11:30 - 11:35	Discussion

11:35 - 11:40	Wrap-up & Closing comments
	Wendy Martin, GBR

12:00 - 12:25	Basic science
	Talya Dayton, ESP

12:25 - 12:50	Clinical and translational science
	Timon Vandamme, BEL

12:50 - 13:10	Awards ceremony

13:10 - 13:30	Closing comments and handover to new ENETS Chair